ClinicalTrials.gg
RecruitingNCT04166825Updated Dec 5, 2025

Ovarian Hyperstimulation and Fibrin Clot Properties.

An interventional study of fibrin clot properties in Fibrin Blood Clot, Infertility, Female and Endometriosis, sponsored by Jagiellonian University. Recruiting at 1 site in Poland. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-12-05.

Sponsored by Jagiellonian University · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as recruiting.
  • Started Nov 2019; still recruiting 7 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Non-randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

The impact evaluation of ovarian hyperstimulation on coagulation and fibrinolysis in infertile women.

Comparative analysis between different ovarian stimulation protocols on thrombin formation and efficiency of fibrinolysis in women diagnosed with infertility.

Read the detailed description

Infertility is a common problem. Assisted reproductive techniques (ART) increases the chance of getting pregnant by couples undergoing such treatment. Unfortunately, the numer of live births after ART remains still low. Over the past three decades, physicians have tried to improve infertility diagnosis and increase its successful treatment. An effort aimed at increasing effectivenes of diagnosis resulted in hypothesis that one of probable reasons of infertility may be the occurrence of microclots, which worsen implantation and embryos development. There are currently no published studies describing the effects of different ovarian hyperstimulation protocols on hemostasis (coagulation and fibrinolysis).

The parameters of thrombin generation and efficiency of fibrinolysis will be evaluated in women qualified for ovarian hyperstimulation. The study may improve the effectiveness of ART.

02

Conditions studied

  • Fibrin Blood Clot
  • Infertility, Female
  • Endometriosis

Keywords

  • coagulation
  • fibrinolysis
  • ovarian hyperstimulation
  • infertility
03

In context

Infertility, Female

553 studies on the registry are indexed under Infertility, Female; 133 are open to participants now.

This study's planned enrollment of 300 is above the median of 100 across 378 interventional studies indexed under Infertility, Female.

Browse Infertility, Female studies →

Lead sponsor

Jagiellonian University is the lead sponsor of 161 studies on the registry; 34 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • infertility defined based on the WHO 2010 criteria

Exclusion criteria

Exclusion Criteria:

  • ovarian involvement
  • oral use within previous 3 months
  • dienogest therapy within 3 months until ART
  • thrombotic events in the medical history
  • severe hypertension
  • diabetes mellitus
  • the presence of known VTE risk factors, including obesity, recent major surgery with prolonged immobilization or trauma,
  • deficiency of antithrombin, protein C or protein S,
  • antiphospholipid syndrome,
  • known ,
  • any chronic inflammatory diseases (e.g. rheumatoid arthritis)
  • advanced chronic renal disease (estimated [eGFR] \<30 ml/min),
  • (INR) more than 1.2 at the day of blood draw
  • pregnancy.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Active comparator
    Long protocol

    Ovarian hyperstimulation started on day 2 or 3 of the cycle with daily subcutaneous injections of recombinant human FSH (follitropin α, Gonal F®, Merck Serono) and/or urinary human menopausal gonadotropin (menotropin, Menopur®, Ferring GmbH) or mixed recombinant human FSH/LH (Pergoveris®, Merck Serono) with a starting dose of 87.5-250 IE/day

    Diagnostic Test: fibrin clot properties

  • Active comparator
    Short protocol

    Ovarian hyperstimulation with a GnRH-antagonist consisted of the use of ganirelix (Orgalutran®, MSD) from the 6th day of stimulation until it's end at the daily dose of 0.25 mg

    Diagnostic Test: fibrin clot properties

  • Active comparator
    Clomiphene citrate

    Ovarian stimulation with clomiphene citrate (Clostilbegyt®, EGIS) 50 mg daily per os form 3rd to 7th day of the cycle

    Diagnostic Test: fibrin clot properties

  • Active comparator
    Letrozole

    Ovarian stimulation with letrozole (Lametta®, Vipharm) 2.5 mg daily per os form 3rd to 7th day of the cycle

    Diagnostic Test: fibrin clot properties

  • Active comparator
    Gonadotropins

    Ovarian hyperstimulation started on day 2 or 3 of the cycle with daily subcutaneous injections of recombinant human FSH (follitropin α, Gonal F®, Merck Serono).

    Diagnostic Test: fibrin clot properties

Interventions

  • Diagnostic testfibrin clot properties

    Assessment of thrombin generation and efficiency of fibrinolysis.

06

What researchers measure

Primary outcomes

  1. Fibrin clot properties before and after the ovarian hyperstimulation.

    Coagulation (endogenous thrombin potential) and fibrinolysis (F1+2, clot lysis time)parameters assessment.

    Time frame: 4 months

Secondary outcomes

  1. Endometriosis and fibrin clot properties.

    Changes of fibrin clot properties before and after ovarian hyperstimulation in women with endometriosis - Coagulation (endogenous thrombin potential) and fibrinolysis (F1+2, clot lysis time)parameters assessment.

    Time frame: 1 cycle

07

Study locations

1 of 1 sites recruiting
  • Department of Gynecological Endocrinology Jagiellonian University Medical College
    Krakow, Małopolska 30-501, Poland
    Recruiting
    • Magdalena Piróg, MD, PhD · Contactmagda.m.pulka@gmail.com · 604514915
    • Olga Kacalska - Janssen, MD, PhD · Sub investigator
    • Joanna Natorska, MD, PhD · Sub investigator
    • Robert Jach, MD, PhD · Sub investigator
08

References and documents

Publications

  • Pirog M, Jach R, Zabczyk M, Natorska J. Unfavorably altered fibrin clot properties in women with unexplained infertility: association with pregnancy outcomes. Arch Gynecol Obstet. 2026 Apr 27;313(1):173. doi: 10.1007/s00404-026-08418-y. PubMed 42043574 ↗
  • Pirog M, Jach R, Zabczyk M, Natorska J. Prothrombotic fibrin clot phenotype in pregnant women after ovarian stimulation: associations with neuropeptides. Hormones (Athens). 2026 Mar 26. doi: 10.1007/s42000-026-00774-3. Online ahead of print. PubMed 41888469 ↗
  • Pirog M, Kacalska-Janssen O, Jach R, Wyroba J, Chrostowski B, Zabczyk M, Natorska J. GnRH Antagonist Protocol Enhances Coagulation During Controlled Ovarian Stimulation for IVF. Reprod Sci. 2022 Dec;29(12):3521-3531. doi: 10.1007/s43032-022-01026-6. Epub 2022 Jul 12. PubMed 35821349 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2019 (actual). Primary completion is estimated for Jan 2026, 74 months after the start.

Of 143 non-industry interventional studies with no phase under Infertility, Female, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 74 months is above that.

Counting every sponsor, half of 156 studies reached it within 23 months; a quarter within 9 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2019
First posted
Nov 18, 2019
StartActual
Nov 18, 2019
Primary completionEst.
Jan 2026
CompletionEst.
Jan 2026
Last update
Dec 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04166825
Responsible party
Magdalena Piróg, MD (Principal Investigator, Jagiellonian University) — Principal investigator
First posted
Nov 18, 2019
Start date
Nov 18, 2019
Primary completion
Jan 2026 (estimated)
Completion
Jan 2026 (estimated)
Last update
Dec 5, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion